Zhang et al. developed an ITE monotherapy that targets B7-H6/CD3 [29] that facilitated the formation of cytolytic synapses between T and cancer cells, thereby increasing the cytotoxicity and infiltration of T cells, resulting in cancer regression. The gene discussed is NCR3LG1; the disease is cancer.